期刊文献+

通心络胶囊联合卡维地洛治疗慢性心力衰竭临床分析 被引量:2

Clinical analysis of Tongxinluo Capsule combined with carvedilol in treatment of chronic heart failure
下载PDF
导出
摘要 目的观察通心络胶囊联合卡维地洛治疗慢性心力衰竭的临床疗效和安全性。方法选择慢性心力衰竭患者60例,随机分为对照组和观察组各30例,对照组常规给予强心甙、利尿剂、血管扩张剂和血管紧张素转换酶抑制剂等治疗。观察组在对照组治疗基础上应用通心络胶囊每次4粒(每粒0.26 g),每日3次;同时联合卡维地洛5~20 mg口服,每日2次;两组疗程均为8周。结果观察组心功能改善的总有效率为90.0%,高于对照组的70.0%,两组比较差异有统计学意义(P〈0.05)。治疗后观察组心排出量(CO)、每搏输出量(SV)、左心室舒张末期内径(LVDd)、左心室射血分数(LVEF)均有显著改善(P〈0.05);而对照组只有LVEF明显改善(P〈0.05),且观察组LVEF改善优于对照组(P〈0.05)。结论应用通心络胶囊联合卡维地洛治疗慢性心力衰竭具有明显逆转左心室肥厚和改善患者的左心收缩功能。可作为治疗慢性心力衰竭的一线用药。 Objective To observe the effect and safety of Tongxinluo Capsule combined with carvedilol in treating chronic heart failure. Methods 60 patients with chronic heart failure due to coronary or hypertensive heart disease were selected and randomly divided into the control group and the observation group,30 cases in each group. The control group was conventionally given the treatment including cardiac glycosides, diuretics, vasodilators and angiotensin-converting enzyme inhibitor treatment. On the basis of the conventional treatment in the control group, the observation group received Tongxinluo Capsule 4 cap- sules per time, 3 times per day and simultaneously oral carvedilol 5-20 mg twice daily. The total treatment duration in the two groups was 8 weeks. Results The effective rate of the cardiac function improvement was 90.0% in the observation group and higher than 70.0% in the control group, showing statistical difference between the two groups (P〈0.05). After treatment, cardiac output (C O ), stroke volume ( SV ), left ventric ular end-diastolic diameter (LV Dd ), left ventricular ejection fraction (LVEF) in the observation group were significantly improved (P〈0.05),while only LVEF in the control group was significantly improved (P〈 0.05). The improvement of LVEF in the observation group was better than that in the control group (P〈0.05). Conclusion Tongxinluo Capsule combined with carvedilol in treating chronic heart failure obvious effects to convert left ventricular hypertrophy and improve the left ventricular systolic function and can be used as first-line drug in the treatment of chronic heart failure.
作者 谢盛
出处 《现代医药卫生》 2012年第10期1463-1464,共2页 Journal of Modern Medicine & Health
关键词 心力衰竭 慢性病 胶囊 通心络 卡唑类 Heart failure Chronic disease Capsules Tongxinluo Carbazoles
  • 相关文献

参考文献9

二级参考文献41

  • 1Bristow MR. Mechanism of action of betablocking agenes in heart failure[J].Am Cardiol, 1997,80 : 26 - 40. 被引量:1
  • 2叶任高.内科学[M](第2版)[M].北京:人民卫生出版社,2001.308-309. 被引量:1
  • 3Ruffolo RR,Feuerstein GZ.Pharmacology of earvedilol:rationale for use in hypertension, coronary artery disease,and congestive heart failure.Cardiovasc Drug Ther,1997,11(suppll):247 - 256. 被引量:1
  • 4Suzuki Y, Tanaka M,Sohmiya M,et al.Antioxidant properties of carvedilol:inhibition of lipid peroxidation, protein oxidation and superoxide generation. Neurol Res, 2003,25(7) : 749 - 753. 被引量:1
  • 5Malfatto G, Facchini M, Branzi G.Long-term treatment with the beta-blocker carvedilol restores autonomic tone and responsiveness in patients with moderate heart failure. J Cardiovasc Pharmacol, 2003,42(1): 125-131. 被引量:1
  • 6Herman RB,Jesudason PJ,Mustafa AM,et al.Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol,2003,55(2): 134- 138. 被引量:1
  • 7Palazzuoli A, Calabria P, Verzuri MS,et al.Carvedilol: something else than a simple betablocker? Eur Rev Med Pharmacol Sei,2002,6(6) :115 - 126. 被引量:1
  • 8Padi SS, Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron, 2002,92(3): 685 -692. 被引量:1
  • 9Yang SP, Ho LJ, Lin YL, et al. Carvedilol, a new antioxidative beta-blocker,blocks in vitro human peripheral blood T cell activation by downregulating NF- kappaB activity. Cardiovasc Res, 2003, 59(3):776 - 787. 被引量:1
  • 10Oliveira PJ, Esteves T, Rolo AP, et al. Carvedilol: relation between antioxidant activity and inhibition of the mitochondrial permeability transition. Rev Port Cardiol,2003,22(1): 55-62. 被引量:1

共引文献2460

同被引文献164

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部